Loading...
Market
How will Novo Nordisk's stock price change by end of 2025 due to Medicare's price negotiation?
2
Resolution / Starting Odds
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Stock market reports and financial analysis
Story
Medicare to Negotiate Ozempic Prices Under Inflation Reduction Act, Saving $200 Billion
Jan 17, 2025, 04:04 PM
The Biden administration has announced that Medicare will include 15 additional drugs in its price negotiation program, including Novo Nordisk's blockbuster weight loss medications Ozempic and Wegovy, which contain semaglutide. These drugs are popular treatments for Type 2 diabetes and obesity but have been scrutinized for their high out-of-pocket costs. The negotiated prices are expected to take effect in 2027 under the Inflation Reduction Act and are projected to save the government more than $200 billion over a decade. The combined cost of these drugs to Medicare is $41 billion. With this second round of negotiations, a total of 25 drugs have now been selected for price reductions, aiming to reduce prescription drug costs for millions of Americans.
View original story
Similar markets
$126 to $150 • 25%
Below $100 • 25%
$100 to $125 • 25%
Above $150 • 25%
No • 50%
Yes • 50%
Yes • 50%
No • 50%
Decrease • 25%
Moderate increase • 25%
No significant change • 25%
Significant increase • 25%
Outperform significantly • 25%
Outperform slightly • 25%
Match performance • 25%
Underperform • 25%
Novo Nordisk outperforms • 25%
Both underperform • 25%
Both perform equally • 25%
Eli Lilly outperforms • 25%
